



Comparison of Multiplex Gastrointestinal Pathogen Panel and Conventional Stool Testing for Evaluation of Diarrhea in Patients with Inflammatory Bowel Diseases

Waseem Ahmad¹ · Nghia H. Nguyen¹ · Brigid S. Boland² · Parambir S. Dulai² · David T. Pride³ · Daniel Bouland⁴ · William J. Sandborn² · Siddharth Singh^{2,5}

Received: 22 May 2018 / Accepted: 9 October 2018 / Published online: 25 October 2018
© Springer Science+Business Media, LLC, part of Springer Nature 2018

Abstract

Background and Aims Gastrointestinal pathogen panels (GPPs) are increasingly being used for evaluation of diarrhea. The impact of these tests on patients with inflammatory bowel diseases (IBD) is unknown. We performed a time-interrupted cohort study comparing GPPs and conventional stool evaluation in patients with IBD with diarrhea.

Methods We included 268 consecutive patients with IBD who underwent GPP (BioFire Diagnostics[®]) ($n = 134$) or conventional stool culture and *Clostridium difficile* polymerase chain reaction testing ($n = 134$) during suspected IBD flare between 2012 and 2016. Primary outcome was composite of 30-day IBD-related hospitalization, surgery, or emergency department visit; secondary outcome was IBD treatment modification.

Results Overall, 41/134 (30.6%) patients tested positive on GPP (18 *C. difficile*, 17 other bacterial infections, and 6 viral pathogens) versus 14/134 patients (10.4%, all *C. difficile*) testing positive on conventional testing. Rate of IBD treatment modification in response to stool testing was lower in GPP group as compared conventional stool testing group (35.1 vs. 64.2%, $p < 0.01$). On multivariate analysis, diagnostic evaluation with GPP was associated with three times higher odds of IBD-related hospitalization/surgery/ED visit (95% CI, 1.27–7.14), as compared to conventional stool testing. This negative impact was partly mediated by differences in ordering provider specialty, with non-gastroenterologists more likely to order GPP as compared to gastroenterologists.

Conclusions In patients with suspected flare of IBD, GPPs have higher pathogen detection rate and lead to lower rate of IBD treatment modification. A diagnostic testing strategy based on GPPs is associated with higher hospital-related healthcare utilization as compared to conventional stool testing, particularly when utilized by non-gastroenterologists.

Keywords Diagnostic testing · Nucleic acid detection · Overdiagnosis · Complications

Electronic supplementary material The online version of this article (<https://doi.org/10.1007/s10620-018-5330-y>) contains supplementary material, which is available to authorized users.

✉ Siddharth Singh
sis040@ucsd.edu

¹ Department of Internal Medicine, University of California San Diego, La Jolla, CA, USA

² Division of Gastroenterology, University of California San Diego, 9452 Medical Center Drive, ACTRI 1W501, La Jolla, CA 92093, USA

Introduction

Gastrointestinal infections present an important conundrum in the management of inflammatory bowel disease (IBD). Gastrointestinal infections, in particular *Clostridium difficile* (CDI), are common in patients with IBD [1]. In patients

³ Department of Pathology and Infectious Diseases, University of California San Diego, La Jolla, CA, USA

⁴ Division of Hospital Medicine, University of California San Diego, La Jolla, CA, USA

⁵ Division of Biomedical Informatics, University of California San Diego, La Jolla, CA, USA

with known IBD, a flare of IBD may be indistinguishable from acute infectious gastroenteritis with patients presenting with diarrhea, rectal bleeding, and abdominal pain; moreover, gastrointestinal infections as well as antibiotic use may themselves trigger a flare of IBD [2]. Hence, stool testing for gastrointestinal infection is an essential first step in the evaluation of an IBD patient presenting with symptoms of a flare. Conventionally, stool testing has been performed using stool cultures for bacterial pathogens and *Clostridium difficile* toxin testing using polymerase chain reaction (PCR).

Over the last 5 years, the United States Food and Drug Administration has approved multiplex gastrointestinal pathogen panels (GPPs) for evaluation of patients suspected to have acute infectious gastroenteritis [3]. These tests simultaneously evaluate for a large number of bacterial, viral, and/or parasitic pathogens by detection of microbial nucleic acids. Compared to conventional stool tests, GPP offers several advantages such as reduced technical expertise, shorter turnaround times, consolidated workflow, and increased sensitivity [3, 4]. However, GPP is highly sensitive and cannot distinguish between viable, replicating organisms that are responsible for disease and non-viable pathogens or remnant nucleic acid (colonization); several “pathogens” on this panel such as *E. coli* species (enteropathogenic *E. coli* [EPEC] or enteroaggregative *E. coli* [EAEC]), adenovirus, astrovirus, and *Salmonella* may be present in the stool of asymptomatic individuals, or may be shed for long periods of time after resolution of disease [5]. This may be problematic in patients who have underlying chronic gastrointestinal diseases such as IBD, wherein positive results may be truly pathogenic or may represent overdiagnosis with misattribution of symptoms to infections, inappropriate use of antibiotics, and delay in IBD-directed therapy.

There has been very limited comparative evaluation of clinically relevant outcomes in patients with IBD who undergo GPP as compared to conventional stool testing. In a study from Mayo Clinic, based on conventional stool examination, non-CDI bacterial infections were very uncommon (< 3%) in patients with IBD and were largely inconsequential [6]. In contrast, in another referral center study, ~ 14% patients with IBD who underwent GPP were positive for non-CDI infections, of which one-third were treated with antibiotics; these patients were less likely to undergo IBD treatment modification as compared to patients who tested negative. However, this study did not evaluate downstream patient-important consequences of testing and associated treatment decisions [7]. Hence, we conducted a retrospective cohort comparing risk of clinically relevant outcomes (30- and 90-day risk of surgery, hospitalization, and/or emergency department [ED] visits) in biologic-exposed patients with IBD who underwent conventional stool testing (stool culture for bacterial pathogens and *C. difficile* toxin PCR testing) or multiplex GPP for evaluation of suspected IBD

flare. Our study was designed to evaluate the impact of diagnostic approach, rather than focusing on results of specific tests, on outcomes of patients [8].

Methods

Study Design

We performed a retrospective cohort study in biologic-exposed patients with IBD seen and followed at University of California San Diego (UCSD). Patients were included if they had a definitive diagnosis of IBD (based on clinical history, endoscopy, radiology, and/or histology), were treated with biologic agents any time between January 1, 2012, and December 31, 2016, were followed at UCSD for > 6 months, and underwent stool testing for suspected symptoms of IBD flare (diarrhea, rectal bleeding, and/or abdominal pain). This study was approved by the UCSD Institutional Review Board (IRB #161914).

Enteric Pathogen Testing

Between 2012 and 2015, infectious evaluation for diarrhea was performed exclusively using conventional stool testing (stool culture and *C. difficile* PCR). *C. difficile* PCR test at our institution detects *C. difficile* toxin B gene (tcdB) and is an FDA-cleared in vitro diagnostic test that has been modified with performance characteristics validated by the UC San Diego Health System Clinical Laboratories. In September 2015, our institution started using GPP, BioFire FilmArray GI Panel[®] (BioFire Diagnostics, Salt Lake City, UT), for both inpatient and outpatient diarrhea evaluation [4]. This test detects nucleic acid from 22 pathogens including 13 bacteria, 5 viruses, and 4 parasites, including *C. difficile* genes for both toxins A (tcdA) and B (tcdB). The GPP is practically used by providers in the outpatient setting, emergency department, and early inpatient setting; it cannot be ordered at our institution for inpatients that have been hospitalized greater than 72 h, as by that point, any diarrheal diagnostic testing is focused on *C. difficile* detection. Processing (hands-on) time per run takes approximately 2 min, there is no separate extraction required, it results return in approximately 1 h, and it reports dichotomous results (detected or not detected) [3]. Between January 1, 2012, and November 30, 2016, at UCSD, we performed 862 stool cultures tests and 2145 GPPs, in both inpatient and outpatient setting in all patients. Approximately 4.2% stool cultures tested positive, and ~ 10% *C. difficile* PCR tests were positive. Of all GPP tests performed, overall positivity is 36% (including *C. difficile* 15.3%, EPEC 9.5%, EAEC 4.9%, norovirus 5.1%, Shigella/enteroinvasive *E. coli* 3.4%, and Campylobacter 2.4%).

Patients who underwent either form of testing during an episode suggestive of a flare were included; for patients who underwent repeated stool evaluation over the course of their follow-up at UCSF, only a single test was included. To avoid differential testing bias based on provider preferences, we performed a time-interrupted cohort study in which all patients included in the conventional testing arm underwent testing between 2012 and 2015 (when that was the only evaluation available), and all patients included in the GPP testing arm had undergone evaluation between 2015 and 2016. While providers from 2015 to 2016 could choose to order conventional testing, GPP, or both, providers often chose only one of the two diagnostic evaluation methods. Since the outcomes were defined at a fixed 30- and 90-day follow-up, differential length of follow-up in these cohorts was inconsequential.

Data Abstraction

We abstracted the following values from the medical records: (a) patient characteristics: age, sex, race or ethnicity, body mass index; (b) disease characteristics: IBD type, phenotype (based on Montreal classification), disease duration, disease location, prior bowel resection, hospitalization within 6 months prior to presentation, CDI, and/or antibiotic use within 12 months prior to presentation; (c) treatment characteristics: current biologic and/or immunomodulator use, prior biologic use, current steroid use, or use within 12 months prior to presentation; (d) flare characteristics: symptoms at presentation (diarrhea, blood in stool, fever, abdominal pain), laboratory variables at presentation (white blood cell count, hemoglobin, C-reactive protein, albumin); (e) enteric pathogen testing: test type, identified pathogen(s), ordering providers (gastroenterologists vs. non-gastroenterologists); and (f) outcomes: composite of IBD-related surgery, hospitalization, and/or ED visit within 30 days or 90 days of enteric pathogen testing, IBD treatment modification (change in corticosteroids, immunomodulators and/or biologic) or initiation of antibiotics following enteric pathogen testing.

Outcomes

Primary outcome of interest was rate of IBD-related surgery, hospitalization, and/or ED visit within 30 days of enteric pathogen testing, regardless of test results. Secondary outcomes were: (a) IBD-related surgery, hospitalization, and/or ED visit within 90 days of enteric pathogen testing, (b) IBD treatment modification in response to enteric pathogen testing (change in corticosteroids, immunomodulators and/or biologic use), and (c) initiation of antibiotics in response to enteric pathogen testing.

We also compared outcomes in patients who tested positive versus negative on corresponding enteric pathogen testing modality. Subgroup analysis of patients with ulcerative colitis or Crohn's disease was also performed.

Statistical Analysis

We evaluated the association between type of enteric pathogen testing and outcomes and covariates using Chi-square test or Fisher's exact test for categorical variables and Student's *t* test for continuous variables. To evaluate the independent association between type of enteric pathogen testing and clinical outcomes, we performed multivariable logistic regression analysis after adjusting for age, prior hospitalization, current biologic and/or steroid use, and C-reactive protein. All hypothesis testing was performed using a two-sided *p* value with a statistical significance threshold < 0.05 . All statistical analyses were performed with Stata MP (StataCorp. 2015. *Stata Statistical Software: Release 14*. College Station, TX: StataCorp LP).

Results

Patient Characteristics

We included 268 symptomatic IBD patients (42.5% with ulcerative colitis; 57.5% with Crohn's disease) who underwent stool testing (50% conventional stool testing; 50% GPP) during the study period. Baseline patient, disease, treatment, and clinical presentation characteristics are summarized (Table 1). Majority of patients presented with diarrhea and/or abdominal pain; 27.6% presented with rectal bleeding; and 7.8% patients had fever at presentation. Overall, 6.7% patients had prior CDI in preceding 12 months. Patients undergoing GPP had longer disease duration (median, 9 vs. 6 years, $p < 0.01$), higher rate of prior bowel resection (43 vs. 26%, $p < 0.01$), and prior anti-TNF exposure (99 vs. 69%, $p < 0.01$), and were more likely to be on biologics at time of enteric pathogen testing (76 vs. 51%, $p < 0.01$). However, these patients who underwent GPP testing were less likely to have been hospitalized in the preceding 6 months (16 vs. 35%, $p < 0.01$), received corticosteroid use within 12 months prior (30 vs. 46%, $p = 0.01$), though there was no difference in current corticosteroid use (19 vs. 24%, $p = 0.46$). Gastroenterologists were more likely to order conventional stool testing over GPP (61 vs. 39%), whereas non-gastroenterologists were more likely to order GPP testing over conventional stool testing (62 vs. 38%).

Table 1 Characteristics of patients with inflammatory bowel diseases who underwent enteric pathogen testing using either conventional stool evaluation or multiplex gastrointestinal pathogen panels

	Conventional stool evaluation (N= 134)	Gastrointestinal pathogen panel (N= 134)	p value
Patient characteristics			
Age (years), mean ± SD	38.9 ± 16.1	41.7 ± 16.1	0.16
Female, n (% total)	74 (55%)	68 (51%)	0.54
Race/ethnicity, n (%)			
White	105 (78%)	97 (72%)	0.03
Black	5 (4%)	5 (4%)	
Hispanic	15 (11%)	15 (11%)	
Asian	6 (4%)	2 (1%)	
Other	3 (2%)	15 (11%)	
BMI (kg/m ²), mean ± SD	24.3 ± 4.9	25.4 ± 6.5	0.13
Disease characteristics			
Duration (years), median (range)	6 (2–13)	9 (5–19)	< 0.01
IBD subtype, n (%)			
Crohn's disease	79 (59%)	75 (56%)	0.71
Ulcerative colitis	55 (41%)	59 (44%)	
CD location, n (%)			
L1	10 (12%)	16 (21%)	0.16
L2	27 (34%)	18 (24%)	
L3	42 (53%)	39 (52%)	
L4	0 (0%)	2 (3%)	
UC location, n (%)			
Pancolitis	28 (51%)	35 (60%)	0.62
Left-sided	17 (31%)	16 (27%)	
Proctitis	10 (18%)	8 (13%)	
Prior abdominal surgery, n (%)			
Last 6 m	10 (7.5%)	9 (7%)	1.0
Prior hospitalization (last 6 m), n (%)	47 (35%)	22 (16%)	< 0.01
Prior antibiotic use (last 12 m), n (%)	37 (28%)	30 (22%)	0.40
Prior CDI (last 12 m), n (%)	14 (10%)	4 (3%)	0.03
Treatment characteristics			
Prior anti-TNF exposure, n (%)	93 (69%)	133 (99%)	< 0.01
Prior steroid use (last 12 m), n (%)	61 (46%)	40 (30%)	0.01
Current medication use			
Immunomodulator use, n (%)	78 (58%)	59 (44%)	0.04
Steroid use, n (%)	32 (24%)	25 (19%)	0.46
Biologic use, n (%)	68 (51%)	102 (76%)	< 0.01
Clinical presentation			
Symptoms at presentation, n (%)			
Diarrhea	115 (86%)	100 (75%)	0.03
Blood in stool	38 (28%)	36 (27%)	0.89
Fever	11 (8%)	10 (7%)	1.0
Abdominal pain	81 (60%)	95 (71%)	0.09
Labs at presentation			
WBC (1000/mm ³), median (range)	8.1 (6.5–10.8)	8.2 (6.7–11.1)	0.59
Hemoglobin (gm/dL), median (range)	12.8 (11.6–13.8)	13.2 (11.4–14.5)	0.41
C-reactive protein (mg/dL), median (range)	0.8 (0.2–3.8)	1.0 (0.2–3.1)	0.77
Albumin (g/dL), median (range)	4.1 (3.7–4.5)	3.9 (3.7–4.4)	0.28

Table 1 (continued)

	Conventional stool evaluation (N=134)	Gastrointestinal pathogen panel (N=134)	p value
Ordering provider			
Gastroenterologists	88 (66%)	57 (43%)	0.01
Non-gastroenterologists	46 (34%)	77 (57%)	
Emergency department	6	25	
Inpatient hospitalization	39	51	
Medicine clinic	1	1	

Bold values are statistical significance ($p < 0.05$)

BMI Body mass index, *CD* Crohn's disease, *CDI* Clostridium difficile infection, *IBD* inflammatory bowel diseases, *TNF* tumor necrosis factor, *UC* ulcerative colitis and *WBC* white blood cell

Table 2 Identification of enteric pathogens in patients with IBD, detected using conventional stool testing or gastrointestinal pathogen panels

	Conventional stool evaluation (N=134)	Gastrointestinal pathogen panel (N=134)
Positive test, n (%)	14/134 (10%)	41/134 (31%)
Total # organisms identified	14	51
Bacteria, n	14	42
CDI	14/14	18/51
Non-CDI bacteria	0/14	24/51
<i>Escherichia coli</i> species	0	19
EAEC		6
EPEC		11
ETEC		2
Campylobacter	0	1
Salmonella	0	1
Yersinia		1
Plesiomonas		1
Shigella		1
Viral, n	0/14	9/51
Norovirus		6
Rotavirus		2
Adenovirus		1
Parasites, n	0	0
Co-infections, n	0	8
Treated with antibiotics, n	26	35
CDI	14	15
Non-CDI bacteria	0	12
Alternative indication	12	8

CDI Clostridium difficile infection, *EAEC* enteroaggregative *E. coli*, *EPEC* enteropathogenic *E. coli* and *ETEC* enterotoxigenic *E. coli*

Enteric Pathogen Testing

Overall, 41/134 (30.6%) patients tested positive using GPPs, with 51 total organisms identified. The most common enteric pathogens detected by GPP were *E. coli* species (19,

14.2%; mainly enteropathogenic *E. coli* [EPEC] or enteroaggregative *E. coli* [EAEC]) and CDI (18, 13.4%). Other pathogens detected included Campylobacter, Salmonella, Yersinia, Plesiomonas, Shigella, norovirus, rotavirus, and adenovirus (Table 2). Eight (6.0%) patients were noted to have co-infections, with two or more detected pathogens. Overall, these GPP positivity rates were comparable to rates observed institution-wide regardless of underlying disease (36%). Patients undergoing GPP did not undergo concomitant conventional stool testing. In contrast, 14/134 (10.4%) patients undergoing conventional stool testing had positive tests with 14 total organisms identified, all of which were CDI; no cases of non-CDI bacterial pathogens were identified on conventional stool culture. This was also comparable to overall institution-wide *C. difficile* PCR positivity (10%) and stool culture positivity (4.2%).

Impact of Enteric Pathogen Testing on Clinical Outcomes

Primary Outcome

Overall, 24 (18%) patients underwent GPP testing underwent IBD-related surgery, hospitalization, and/or ED visit within 30 days of testing, as compared to 20 (15%) patients who underwent conventional stool testing (Table 3). Similar results were obtained when evaluating 90-day rates of IBD-related surgery, hospitalization, and/or ED visit (Table 3), and in patients with ulcerative colitis and Crohn's disease (eTable 1 and 2). On multivariable logistic regression, after adjusting for age, prior hospitalization, current biologic and/or steroid use, and C-reactive protein, diagnostic evaluation with GPP was associated with three times higher odds of IBD-related hospitalization/surgery/ED visit within 30 days of testing (OR, 3.03; 95% CI, 1.27–7.14), as compared to conventional stool testing (Table 4). Besides enteric pathogen testing modality, current corticosteroid use and high C-reactive protein were associated with increased risk of outcomes, whereas current biologic use was protective against hospitalization-related healthcare utilization.

Table 3 Association between enteric pathogen testing and 30- and 90-days risk of hospitalization-related healthcare utilization and change in IBD management

	Conventional stool evaluation (N= 134)	Gastrointestinal pathogen panel (N= 134)	p value
Primary outcome (30 day)			
Hospitalization-related healthcare utilization (30 day)	20 (15%)	24 (18%)	0.51
ED visit (30 day)	20 (15%)	24 (18%)	0.51
Hospitalization (30 day)	18 (13%)	19 (14%)	0.86
Surgery (30 day)	9 (7%)	8 (6%)	0.80
Sensitivity analysis (90 day)			
Hospitalization-related healthcare utilization (90 day)	30 (22%)	34 (25%)	0.57
ED visit (90 day)	30 (22%)	34 (25%)	0.57
Hospitalization (90 day)	27 (20%)	27 (20%)	1.0
Surgery (90 day)	11 (8%)	8 (6%)	0.48
Secondary outcome			
Change in IBD Management, n (%)			
Change in IBD	86 (64%)	47 (35%)	< 0.01
Addition of corticosteroids	46 (34%)	27 (20%)	0.03
Change in immunomodulators	27 (20%)	14 (10%)	< 0.01
Change in biologics	56 (42%)	21 (16%)	< 0.01

Bold values are statistical significance ($p < 0.05$)

ED Emergency department, IBD inflammatory bowel diseases

Table 4 Factors associated with increased risk of 30 day of hospitalization-related healthcare utilization based on multivariate logistic regression analysis adjusting for (A) age, prior

Variables	Multivariate ^a	
	OR (95% CI)	p value
Current steroid use	3.09 (1.32–7.21)	0.009
Current biologic use	0.28 (0.12–0.65)	0.003
C-reactive protein (per 1 mg/dl)	1.11 (1.04–1.20)	0.003
GI pathogen panel versus conventional stool testing	3.03 (1.27–7.14)	0.013
Adding ordering provider as an additional variable		
Current steroid use	2.89 (1.21–6.89)	0.016
Current biologic use	0.33 (0.14–0.78)	0.011
C-reactive protein (per 1 mg/dl)	1.08 (1.00–1.16)	0.048
GI pathogen panel versus conventional stool testing	2.00 (0.81–4.95)	0.132
Non-GI providers versus GI providers	3.73 (1.34–10.36)	0.011

Bold values are statistical significance ($p < 0.05$)

^aMultivariate model inclusive of: age and hospitalization within last 6 months

To assess whether impact of GPP testing on outcomes may be influenced by ordering provider, we added ordering provider to the multivariable model (Table 4). Non-gastroenterologist as ordering provider was independently associated with higher odds of IBD-related hospitalization/surgery/ED visit within 30 days of testing (OR, 3.73; 95% CI, 1.34–10.36), whereas the independent impact of GPP testing was not significant.

Secondary Outcomes

IBD Treatment Modification Patients who underwent GPP testing were significantly less likely to undergo IBD treatment modification in response enteric pathogen testing as compared to patients who underwent conventional stool testing (35 vs. 64%, $p < 0.01$). Patients undergoing GPP testing were less likely to have addition of corticosteroids, change

in biologics as well as immunomodulator use (Table 3). These results were stable in subgroup analyses in patients with ulcerative colitis or Crohn's disease (eTable 1 and 2).

Antibiotic Use Thirty-five (26.1%) patients who underwent GPP received antibiotics compared to 26 (19.4%) patients undergoing conventional stool testing ($p=0.24$). Among GPP-positive patients, 15 (42.9%) received antibiotics for CDI, 12 (34.3%) received antibiotics for non-CDI bacteria, and 8 (22.9%) patients received antibiotics for alternative indications (suspected pouchitis, perianal fistula, suspected intra-abdominal abscess, and/or suspected gastrointestinal infection); 3 patients detected to have CDI on GPP testing did not receive antibiotics. Among patients who were positive on conventional stool testing, 14 (53.8%) patients received treatment for CDI and 12 (46.2%) received antibiotics for alternative indications.

Enteric Pathogen Test Positivity Versus Negativity

There was no significant difference in 30- or 90-day rates of IBD-related surgery, hospitalization, and/or ED visit between patients who tested positive or negative on GPP, and in patients who tested positive or negative on conventional stool testing (eTable 3). Numerically, rate of addition of corticosteroids was lower in patients who tested positive versus negative on GPP testing (24 vs. 12%, $p=0.13$). On multivariate logistic regression among a subset of patients who underwent GPP testing, test positivity versus negativity did not significantly affect risk of 30-day hospitalization-related healthcare utilization (data not shown).

Discussion

In this time-interrupted, retrospective cohort study of 268 patients with IBD, who underwent either conventional stool testing using stool culture and *C. difficile* toxin PCR testing or multiplex GPP for symptoms suggestive of IBD flare, we made several key observations. First, enteric pathogen positivity was almost three times higher with GPP testing than conventional stool testing in patients with IBD; this rate aligns with overall GPP test positivity at our center across all patient populations. Overall rates of CDI detection were comparable between both tests, but GPP identified 19 additional patients as having non-CDI bacterial infections, primarily *E. coli* species (EPEC and EAEC), and 4 patients with viral pathogens; conventional stool cultures were negative for non-CDI bacteria. Second, after adjusting for important covariates, patients who underwent GPP testing had three times higher odds of having IBD-related surgery, hospitalization, or ED visit within 30 days of testing, as compared to patients who underwent

conventional stool testing. This effect was partly mediated by ordering providers. Patients who underwent stool testing by non-gastroenterologists versus gastroenterologists experienced higher rates of adverse outcomes. This may be related to challenges in test interpretation and action by non-gastroenterologists, rather than actual test findings. This is apparently based on our observation that patients undergoing GPP testing were more likely to receive antibiotics, and less likely to have their IBD-related medications changed, as compared to patients who underwent conventional stool testing.

By specifically focusing on impact of a diagnostic approach (GPP vs. conventional stool testing), rather than focusing on test results, on patient-important outcomes, we are able to directly inform clinical practice. Our findings suggest that GPP testing to rule out infections in IBD patients presenting with symptoms suggestive of flare is associated with adverse patient outcomes with higher rates of hospitalization-related healthcare utilization. We hypothesize that higher enteric infection positivity on GPP testing leads to misattribution of IBD symptoms to infections especially by non-gastroenterologists, and consequent delay in IBD-related treated modification and/or excessive use of antibiotics resulting in higher rates of ED visit, hospitalization, and/or surgery. Based on these findings, GPP testing in patients with IBD, especially when applied by non-gastroenterologists, likely represents low-value care with potential for harm. As such, limiting diagnostic testing to *C. difficile* evaluation may be most appropriate at this time due to its clinical significance within this population.

GPPs were approved by the FDA for rapid and simultaneous detection of multiple gastrointestinal pathogens simultaneously in patients with signs and symptoms suggestive of gastrointestinal infections [4, 5]. While several cross-sectional studies have confirmed higher sensitivity of these tests, there has been very limited evaluation of downstream consequences of GPP testing on clinically relevant outcomes. Concerns regarding misattribution of symptoms or misdiagnosis of infection in patients with asymptomatic colonization as well as healthcare provider confusion of interpretation of test results (such as EPEC or EAEC positivity, detection of multiple pathogens) with broad implementation of these tests have been raised [3, 4]. In hospitalized patients, inappropriately treating GPP-positive asymptomatic patients with colonization can lead to unnecessary patient isolation, longer length of stay, poor antibiotic stewardship, and institutional penalties for artificially high infectious diarrhea rates. Similar to IBD, overreliance on GPP testing may potentially delay diagnosis and treatment of other non-infectious diarrhea that may be seen in other immunocompromised patients (e.g., post-chemotherapy), organ transplant recipients, patients with human immunodeficiency virus, etc.

Patients with IBD represent a unique population when using GPPs based on the overlap in symptoms between gastrointestinal infections and IBD flare, dysbiosis with higher baseline prevalence of specific and potentially pathogenic *E. coli* species, such as adherent-invasive *E. coli* in patients with IBD, as well as potential for IBD flare due to potentially pathogenic bacteria or subsequent antibiotic exposure [2, 9]. There has been limited evaluation of GPPs in patients with IBD. In a single-center study, Axelrad and colleagues evaluated outcomes in 214 symptomatic patients with IBD who underwent 295 GPP using BioFire Film Array and *C. difficile* PCR testing [7]. In their cohort, 12.9% tested positive for CDI, and 13.9% tested positive on the GPP for other non-CDI pathogens (primarily *E. coli* species), comparable to our cohort. Approximately 50% patients who tested positive for non-CDI bacterial pathogens were treated with antibiotics, as compared to 34.3% in our cohort. Comparing patients with positive test results on GPP for non-CDI pathogens and negative tests, they did not observe any significant differences in rates of hospitalization or surgery, though rate of IBD treatment modification was higher in those with negative results. In another single-center study of 131 patients with IBD (89% inpatients, 47% on biologics, 88% with objective evidence of active IBD) published only in abstract form, by Limsrivilai and colleagues, ~30% tested positive for enteric pathogens on GPP. GPP positivity was significantly higher in patients with active IBD-related inflammation (33 vs. 6% in patients without active IBD) [10]. They observed lower rates of escalation of IBD-related therapy and surgery in the short term in those who tested positive on GPP, as compared to those who tested negative, interpreting that short-term course of IBD may be more benign in those who test positive on GPP as compared to those who test negative. However, it is unclear whether this represents in-hospital outcomes or longer-term outcomes, and whether this may be due to a diagnostic dilemma that treating clinicians faced, resulting in potential delay in IBD treatment modification in this retrospective study. In contrast, in a recent study from Mayo Clinic using conventional stool testing in IBD patients presenting with flare, rate of non-CDI bacterial infections was very low (<3%) and did not influence disease course over 1 year, as compared to IBD patients who tested negative for infection or in patients with CDI; similar to this study, conventional stool testing in our study did not identify a single non-CDI pathogen [6]. Furthermore, a recent study from Columbia University Medical Center using GPP testing in IBD patients presenting with flare showed that GPP-positive patients treated with antibiotics for non-CDI had no difference in outcomes at median follow-up of 10.5 months compared to untreated GPP-positive patients for non-CDI [11]. While further studies assessing outcomes for non-CDI in IBD patients are needed, currently a *C. difficile* toxin PCR only diagnostic strategy and/or increasing scrutiny prior to

prescribing antibiotics for a positive GPP test is warranted. To our knowledge, ours is the first study that directly compares patient outcomes in patients who underwent GPP testing versus those who underwent conventional stool testing. GPP testing, regardless of test results, was associated with higher hospitalization-related healthcare utilization, along with lower rates of IBD treatment modification.

Our study has several limitations, intrinsic to its retrospective design. First, a causal association between GPP testing and adverse patient outcomes cannot be established. This observation is likely multifactorial, with final decisions on IBD management and stool testing interpretation made based on case-by-case basis by treating physicians, with little evidence-based guidance. We were unable to explicitly test our hypothesis that delay in modification of IBD-related therapies directly contributed to increased healthcare utilization. Second, we designed our study to evaluate the impact of diagnostic approach, rather than focusing on results of specific tests, on outcomes of patients, as is recommended in evaluating quality of evidence supporting diagnostic tests [8]. Our study was not powered to detect differences in outcomes in patients with positive or negative results on GPP testing; rather, ours was a convenience sample of biologic-exposed patients with IBD seen and followed at a tertiary center over a 5-year period over which we transitioned from conventional stool testing to GPP. To maintain independence of individual subjects, we counted each patient only once, though most patients expectedly underwent multiple stool tests. Third, simultaneous GPP and CDI testing for toxin was not performed. While there has been no study to assess diagnostic performance of GPP against “gold standard” (i.e., stool culture for bacterial pathogens, etc.) among IBD patients, not performing concomitant stool testing with GPP and conventional methods prevents the ability to accurately determine whether positivity on GPP was indicative of active infection. Fourth, our study population included a mix of outpatients and inpatients, seen in multiple different settings such as a primary care clinic, gastroenterology clinic, a specialized IBD clinic, ED or inpatient hospitalization with threshold and experience for testing likely different between providers in each setting. Fifth, providers could choose to order conventional testing, GPP, or both as diagnostic testing was not randomized from 2015 to 2016. As such, selection bias could have occurred if certain providers preferentially opted for one testing method. However, there is low suspicion for significant differences in patient or disease characteristics for IBD patients undergoing either test in this time period.

In conclusion, based on a comparative retrospective cohort study in biologic-exposed patients with IBD presenting with symptoms suggestive of IBD flare, GPP testing is associated with increased risk of 30-day IBD-related ED visit, hospitalization, or surgery, higher rate of antibiotic

prescription and lower rate of IBD-related treatment modification. GPP tests were more likely to be performed by non-gastroenterologists, suggesting that interpretation and downstream actions by non-gastroenterologists may contribute to adverse outcomes seen in these patients. We recommend that positive test results on GPPs should be interpreted cautiously, with confirmation of non-CDI bacterial pathogens with stool culture where possible, before attributing symptoms to infection, rather than underlying IBD. This should not delay potential modification of IBD-directed therapy, which would be required in a majority of patients. Additionally, due to low rate of non-CDI bacterial culture positivity, conventional stool testing in IBD patients may be limited to *C. difficile* toxin PCR. Prospective studies directly evaluating the impact of GPP testing in patients with IBD are warranted, with assessment of etiologic predictive value of tests [12].

Authors' contribution Study concept and design were conceived by WA, WJS, and SS. Acquisition of data was made by WA. Analysis and interpretation of data were carried out by WA, NHN, and SS. The manuscript was drafted by WA and SS. Critical revision of the manuscript for important intellectual content was performed by NHN, BSB, PSD, DTP, DB, and WJS. The final manuscript was approved by WA, NHN, BSB, PSD, DTP, DB, WJS, and SS. Dr. Siddharth Singh who was the guarantor of the article had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Compliance with ethical standards

Conflict of interest None of the authors declare any potential conflicts of interest related to the contents of this manuscript. Dr. Bolland has served as a consultant for Abbvie and has received research grants from Takeda and Janssen. Dr. Dulai has served as a consultant for Takeda and has received research grants from Takeda and Pfizer. Dr. Sandborn reports consulting fees from University of Western Ontario (owner of Robarts Clinical Trials, Inc), Abbvie, Akros Pharma, Allergan, Ambrx Inc., Amgen, Ardelyx, Arena Pharmaceuticals, Atlantic Pharmaceuticals, Avaxia, Biogen, Boehringer Ingelheim, Bristol Meyers Squibb, Celgene, Conatus, Cosmo Technologies, Escalier Biosciences, Ferring, Ferring Research Institute, Forward Pharma, Galapagos, Genentech, Gilead Sciences, Immune Pharmaceuticals, Index Pharmaceuticals, Janssen, Kyowa Hakko Kirin Pharma, Lilly, Medimmune, Mesoblast, Miraca Life Sciences, Nivalis Therapeutics, Novartis, Nutrition Science Partners, Oppilan Pharma, Otsuka, Palatin, Paul Hastings, Pfizer, Precision IBD, Progenity, Prometheus Laboratories, Qu Biologics, Regeneron, Ritter Pharmaceuticals, Robarts Clinical Trials, Salix, Seattle Genetics, Seres Therapeutics, Shire, Sigmoid Biotechnologies, Takeda, Theradiag, Theravance, Tigenix, Tillotts Pharma, UCB Pharma, Vascular Biogenics, Vivelix; research grants from Atlantic Healthcare Limited, Amgen, Genentech, Gilead Sciences, Abbvie, Janssen, Takeda, Lilly, Celgene/Receptos; payments for lectures/speakers bureau from Abbvie, Janssen, Takeda; and holds

stock/stock options in Escalier Biosciences, Oppilan Pharma, Precision IBD, Progenity, Ritter Pharmaceuticals. Dr. Singh is supported by the American College of Gastroenterology and Crohn's and Colitis Foundation, and has received research grants from Pfizer and AbbVie.

Ethics approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required. This study was approved by the UCSD Institutional Review Board (IRB #161914).

References

1. Landsman MJ, Sultan M, Stevens M, et al. Diagnosis and management of common gastrointestinal tract infectious diseases in ulcerative colitis and Crohn's disease patients. *Inflamm Bowel Dis*. 2014;20:2503–2510.
2. Ananthakrishnan AN, Bernstein CN, Iliopoulos D, et al. Environmental triggers in IBD: a review of progress and evidence. *Nat Rev Gastroenterol Hepatol*. 2018;15:39–49.
3. Binnicker MJ. Multiplex molecular panels for diagnosis of gastrointestinal infection: performance, result interpretation, and cost-effectiveness. *J Clin Microbiol*. 2015;53:3723–3728.
4. Freeman K, Tsertsivadze A, Taylor-Phillips S, et al. Agreement between gastrointestinal panel testing and standard microbiology methods for detecting pathogens in suspected infectious gastroenteritis: Test evaluation and meta-analysis in the absence of a reference standard. *PLoS ONE*. 2017;12:e0173196.
5. Riddle MS, DuPont HL, Connor BA. ACG clinical guideline: diagnosis, treatment, and prevention of acute diarrheal infections in adults. *Am J Gastroenterol*. 2016;111:602–622.
6. Hanada Y, Khanna S, Loftus EV, Jr., et al. Non-clostridium difficile bacterial infections are rare in patients with flares of inflammatory bowel disease. *Clin Gastroenterol Hepatol*. 2017;16:528–533.
7. Axelrad JE, Joelson A, Nobel YR, et al. Enteric infection in relapse of inflammatory bowel disease: the utility of stool microbial PCR testing. *Inflamm Bowel Dis*. 2017;23:1034–1039.
8. Schunemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. *BMJ*. 2008;336:1106–1110.
9. Palmela C, Chevarin C, Xu Z, et al. Adherent-invasive *Escherichia coli* in inflammatory bowel disease. *Gut*. 2018;67:574–587.
10. Limsrivilai J, Stidham RW, Waljee AK, et al. Gastrointestinal infectious agents detected by biofire filmarray GI PCR panel stool testing in active inflammatory bowel disease are common and are associated with a more benign course of IBD. *Gastroenterology*. 2017;152:S606.
11. Axelrad JE, Joelson A, Green PH, et al. Enteric infections are common in patients with flares of inflammatory bowel disease. *Am J Gastroenterol*. 2018. <https://doi.org/10.1038/s41395-018-0211-8>.
12. Gunnarsson RK, Lanke J. The predictive value of microbiologic diagnostic tests if asymptomatic carriers are present. *Stat Med*. 2002;21:1773–1785.